Received Feb 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 34MF9 | — |
a patient that received the Kinrix vaccine that was 4 months old; it was the 2nd dose of DTap and IPV for the patient; This non-serious case was reported by a physician via call center representative and described the occurrence of inappropriate age at vaccine administration in a 4-month-old male patient who received DTPa-IPV (Kinrix) (batch number 34MF9, expiry date 13-FEB-2026) for prophylaxis. On 27-DEC-2024, the patient received Kinrix. On 27-DEC-2024, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: a patient that received the Kinrix vaccine that was 4 months old) and inappropriate schedule of vaccine administered (Verbatim: it was the 2nd dose of DTap and IPV for the patient). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-JAN-2025 A patient that received the Kinrix vaccine that was 4 months old, which led to an inappropriate age at vaccine administration. According to reporter, it was the 2nd dose of DTap and IPV for the patient, which led to an inappropriate schedule of vaccine administered. The vaccine administration facility was the same as primary reporter.